Integra LifeSciences (IART) Stock Price, News & Analysis

Company Overview

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts. Key additions to its portfolio include the integration of Derma Sciences’ regenerative wound care products and the acquisition of Johnson & Johnson’s Codman neurosurgery business. These strategic moves have broadened the company’s offerings across dura repair, nerve regeneration and orthopedic extremities.

Integra’s technologies serve a diverse set of clinical settings, including hospitals, outpatient surgical centers and specialty clinics. With a presence in North America, Europe, Asia-Pacific and Latin America, the company maintains manufacturing and distribution operations on multiple continents to support regional product demand and regulatory compliance. Its global footprint allows for collaboration with healthcare professionals on product development and clinical training initiatives.

The company is guided by a management team with extensive experience in medical device innovation, regulatory affairs and commercial operations. Integra continues to invest in research and development, pursuing new applications in tissue engineering and minimally invasive surgery while maintaining a focus on improving patient outcomes and supporting healthcare providers worldwide.

Key Stats

• Today's Range: $15.49 to $15.83
• 50-Day Range: $13.18 to $15.99
• 52-Week Range: $11.06 to $27.13
• Volume: 112,895 shs
• Average Volume: 1.05 million shs
• Market Capitalization: $1.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.17
• Consensus Rating: Reduce

Integra LifeSciences Stock Analysis - MarketRank™

Integra LifeSciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 570th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Integra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 2 buy ratings, 2 hold ratings, and 4 sell ratings.

Upside/Downside

The consensus price target for Integra LifeSciences is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Integra LifeSciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 2.04%

Earnings Growth

Earnings for Integra LifeSciences are expected to grow by 2.04% in the coming year, from $2.45 to $2.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Integra LifeSciences is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Integra LifeSciences is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Integra LifeSciences has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.48% of the float of Integra LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Integra LifeSciences has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Integra LifeSciences has recently decreased by 2.80%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Integra LifeSciences does not currently pay a dividend.

Dividend Growth

Integra LifeSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.50

Percentage of Shares Shorted

9.48% of the float of Integra LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Integra LifeSciences has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Integra LifeSciences has recently decreased by 2.80%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: 0.20

News Sentiment

Integra LifeSciences has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Integra LifeSciences this week, compared to 6 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Integra LifeSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.54% of the stock of Integra LifeSciences is held by insiders.

Percentage Held by Institutions

84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IART Stock Analysis - Frequently Asked Questions

How have IART shares performed this year?

Integra LifeSciences' stock was trading at $22.68 at the beginning of the year. Since then, IART shares have decreased by 31.2% and is now trading at $15.61.

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) released its earnings results on Thursday, July, 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. The firm's revenue was down .6% on a year-over-year basis.
Read the conference call transcript.

When did Integra LifeSciences' stock split?

Integra LifeSciences's stock split on Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were distributed to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does Integra LifeSciences have any subsidiaries?

Integra LifeSciences subsidiaries include these companies: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and others.

Who are Integra LifeSciences' major shareholders?

Top institutional shareholders of Integra LifeSciences include Assenagon Asset Management S.A. (0.58%), Wedge Capital Management L L P NC (0.08%), Exchange Traded Concepts LLC (0.05%) and Yousif Capital Management LLC (0.03%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen, Lisa Evoli, Witte Jan De and Jeffrey Mosebrook.
View institutional ownership trends.

How do I buy shares of Integra LifeSciences?

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:IART
• CIK: 917520
• Web: www.integralife.com
• Phone: (609) 275-0500
• Fax: 609-750-4277
• Employees: 4,396
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Integra LifeSciences: $16.17
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +3.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 6.40
• P/E Growth: N/A
• Net Income: -$6.94 million
• Net Margins: -30.87%
• Pretax Margin: -34.46%
• Return on Equity: 12.15%
• Return on Assets: 4.32%

Debt

• Debt-to-Equity Ratio: 1.18
• Current Ratio: 1.23
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: $1.61 billion
• Price / Sales: 0.76
• Cash Flow: $4.63 per share
• Price / Cash Flow: 3.39
• Book Value: $20.03 per share
• Price / Book: 0.78

Miscellaneous

• Outstanding Shares: 77,910,000
• Free Float: 75,153,000
• Market Cap: $1.22 billion
• Optionable: Optionable
• Beta: 1.21